138907-70-7

Basic information

• Product Name: ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate
• Synonyms: ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate;5-Amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester
• CAS NO: 138907-70-7
• Molecular Formula: C₁₂H₁₂FN₃O₂
• Molecular Weight: 249.2409832
• Mol File: 138907-70-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 388.74 °C at 760 mmHg
• Flash Point: 188.904 °C
• Appearance: /
• Density: 1.33
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate(138907-70-7)
• EPA Substance Registry System: ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate(138907-70-7)

Safety Data

• Hazardous Substances Data: 138907-70-7(Hazardous Substances Data)

Usage

General Description

Ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate is a chemical compound with the molecular formula C13H12N3O2F. It is a pyrazole derivative that contains an ethyl ester group, an amino group, and a carboxylate group. The compound is commonly used in organic synthesis and pharmaceutical research as a building block for the development of new drugs and bioactive molecules. It has potential therapeutic applications due to its ability to interact with biological systems, and it is also used as a reference standard in analytical and forensic chemistry. The compound's properties and structure make it a valuable tool for studying the reactivity and behavior of pyrazole derivatives in chemical and biological processes.

Upstream product

• 144918-37-6 (E)-ethyl 2-cyano-3-ethoxyacrylate 
• 2924-16-5 3-fluorophenylhydrazine hydrochloride 
• 42466-67-1 ethyl (ethoxymethylene)cyanoacetate 
• 658-27-5 m-fluorophenylhydrazine 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 

Downstream Products

• 1148051-67-5 ethyl 5-diacetylamino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate 
• 1613395-06-4 3-[4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[1-(3-fluorophenyl)-5-(furan-3-yl)-1H-pyrazol-4-yl]pyrrolidin-2-one 
• 1613395-67-7 ethyl 5-iodo-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate 
• 1567126-75-3 5-iodo-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylic acid 
• 1613395-68-8 5-iodo-1-(3-fluorophenyl)-1H-pyrazol-4-yl-carbamic acid 1,1-dimethylethyl ester 
• 1613395-69-9 C₁₈H₂₀FN₃O₃ 
• 1613395-07-5 3-[4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[5-cyclopropyl-1-(3-fluorophenyl)-1H-pyrazol-4-yl]pyrrolidin-2-one 
• 1613395-73-5 C₁₇H₂₀FN₃O₂ 
• 1508092-83-8 5-(3-cyclopropyl)-1-(3-fluorophenyl)-4-amino-1H-pyrazole 
• 1613395-76-8 C₂₁H₂₀ClF₄N₅O₂ 
• 1613395-78-0 C₂₂H₂₂ClF₄N₅O₄S 
• 1613395-80-4 5-iodo-1-(3-fluorophenyl)-1H-pyrazol 
• 1056999-20-2 1-(3-fluorophenyl)-1H-pyrazol-5-amine 
• 138907-82-1 1-(3-fluorophenyl)-1H-pyrazole-4-carboxylic acid 

Relevant articles and documents

Synthesis of pyrazole-carboxamides and pyrazole-carboxylic acids derivatives: Simple methods to access powerful building blocks

Hybrid systems containing pyrazole moiety show a wide spectrum of biological activities. To access novel hybrids with pyrazole ring, in this work we synthesized twenty pyrazole-carboxylic acids and twenty pyrazole-carboxamides, using simple synthetic methods, to be used as building blocks in the development of new structures.

Targeting Pim Kinases and DAPK3 to Control Hypertension

Sustained vascular smooth muscle hypercontractility promotes hypertension and cardiovascular disease. The etiology of hypercontractility is not completely understood. New therapeutic targets remain vitally important for drug discovery. Here we report that Pim kinases, in combination with DAPK3, regulate contractility and control hypertension. Using a co-crystal structure of lead molecule (HS38) in complex with DAPK3, a dual Pim/DAPK3 inhibitor (HS56) and selective DAPK3 inhibitors (HS94 and HS148) were developed to provide mechanistic insight into the polypharmacology of hypertension. In vitro and ex vivo studies indicated that Pim kinases directly phosphorylate smooth muscle targets and that Pim/DAPK3 inhibition, unlike selective DAPK3 inhibition, significantly reduces contractility. In vivo, HS56 decreased blood pressure in spontaneously hypertensive mice in a dose-dependent manner without affecting heart rate. These findings suggest including Pim kinase inhibition within a multi-target engagement strategy for hypertension management. HS56 represents a significant step in the development of molecularly targeted antihypertensive medications. Carlson et al. use crystal structure-guided medicinal chemistry techniques to develop a dual Pim/DAPK3 inhibitor (HS56) that reduces myosin phosphorylation and contractility in smooth muscle. Their findings reveal the contribution of Pim kinases to the pathology of hypertension, suggesting a novel multi-target engagement strategy for molecularly targeted antihypertensive medications.

PYRAZOLO-PYRIDINONE DERIVATIVES AND METHODS OF USE

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of pro-inflammatory cytokine mediated diseases, and in particular, p38 activity mediated inflammation and related conditions. The compounds have a general Fo